Ask-the-Expert Online Conference
- Question from Nunz: Why is tamoxifen recommended for women with LCIS if we aren't sure it's estrogen-receptor-positive?
- Answers - Lynn Hartmann In the large U.S. prevention trial on non-invasive disease women with lobular carcinoma in situ (LCIS) were eligible. There was a significant reduction of their risk of subsequent breast cancer with tamoxifen. So we consider tamoxifen a valid option for women with LCIS.
- Beth Baughman DuPree, M.D., F.A.C.S. LCIS is not cancer; it is a marker for an elevated risk of developing breast cancer. Therefore, the rationale for using tamoxifen is for those cancers that are estrogen-receptor-positive, we are attempting to block those cells from dividing and turning into cancer. Tamoxifen would not be effective in tumors that are estrogen-receptor-negative, but a majority of breast cancers are estrogen-receptor-positive. Therefore, we derive the benefit of tamoxifen from that fact.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.